Modulation of porphyrin binding to serum albumin by pH. 2004

Pavel Kubát, and Kamil Lang, and Pavel Anzenbacher
J. Heyrovský Institute of Physical Chemistry, Academy of Sciences of the Czech Republic, Dolejskova 3, 182 23, Prague 8, Czech Republic.

In this study, we show that the difference in acidity of functional groups in porphyrin photosensitizers provides a meaningful avenue to achieve differential localization and retention of porphyrins in tissues and cells, and in the end could be a positive factor in the photodynamic treatment of cancer (PDT). We have demonstrated that meso-tetraphenylporphyrin derivative with four phosphonate (bond P(double bond O)(bond OH)(2)) moieties exists in aqueous solutions mainly in four forms that differ by a degree of protonation of the porphyrin ring and ionization of the phosphonate group. It is shown that each porphyrin form has different affinities toward the model protein (bovine serum albumin, BSA). Thus pH of the medium significantly modulates the affinity of the phosphonate porphyrin toward BSA. At lower pH (pH 6.0), the phosphonate porphyrin and BSA form a complex with affinity constant of K(b)=6.9 x 10(5) M(-1), while at pH 7.0 the K(b)=6.1 x 10(5) M(-1). At pH 8.0 the association is significantly lower. Because cancerous cells have generally lower pH (pH approximately 6.9) compared to healthy cells (pH approximately 7.4), the pH of such cells could be a decisive factor for cellular retention of the porphyrin in the form of an associate with intracellular proteins. Moreover, we have also demonstrated that the protonation/deprotonation equilibria do not negatively affect the photophysical properties or ability of phosphonate porphyrin to generate singlet oxygen.

UI MeSH Term Description Entries
D011166 Porphyrins A group of compounds containing the porphin structure, four pyrrole rings connected by methine bridges in a cyclic configuration to which a variety of side chains are attached. The nature of the side chain is indicated by a prefix, as uroporphyrin, hematoporphyrin, etc. The porphyrins, in combination with iron, form the heme component in biologically significant compounds such as hemoglobin and myoglobin. Porphyrin
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D012709 Serum Albumin A major protein in the BLOOD. It is important in maintaining the colloidal osmotic pressure and transporting large organic molecules. Plasma Albumin,Albumin, Serum
D013050 Spectrometry, Fluorescence Measurement of the intensity and quality of fluorescence. Fluorescence Spectrophotometry,Fluorescence Spectroscopy,Spectrofluorometry,Fluorescence Spectrometry,Spectrophotometry, Fluorescence,Spectroscopy, Fluorescence
D013053 Spectrophotometry The art or process of comparing photometrically the relative intensities of the light in different parts of the spectrum.
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D017319 Photosensitizing Agents Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms. Photosensitizer,Photosensitizers,Photosensitizing Agent,Photosensitizing Effect,Photosensitizing Effects,Agent, Photosensitizing,Agents, Photosensitizing,Effect, Photosensitizing,Effects, Photosensitizing
D026082 Singlet Oxygen An excited state of molecular oxygen generated photochemically or chemically. Singlet oxygen reacts with a variety of biological molecules such as NUCLEIC ACIDS; PROTEINS; and LIPIDS; causing oxidative damages. Singlet Dioxygen,Dioxygen, Singlet,Oxygen, Singlet

Related Publications

Pavel Kubát, and Kamil Lang, and Pavel Anzenbacher
September 1990, The Biochemical journal,
Pavel Kubát, and Kamil Lang, and Pavel Anzenbacher
April 1956, Archives of biochemistry and biophysics,
Pavel Kubát, and Kamil Lang, and Pavel Anzenbacher
November 1987, Photochemistry and photobiology,
Pavel Kubát, and Kamil Lang, and Pavel Anzenbacher
April 2006, Mini reviews in medicinal chemistry,
Pavel Kubát, and Kamil Lang, and Pavel Anzenbacher
January 2009, Journal of pharmaceutical sciences,
Pavel Kubát, and Kamil Lang, and Pavel Anzenbacher
September 1989, Biochemical pharmacology,
Pavel Kubát, and Kamil Lang, and Pavel Anzenbacher
November 1990, Methods and findings in experimental and clinical pharmacology,
Pavel Kubát, and Kamil Lang, and Pavel Anzenbacher
October 2010, Physical chemistry chemical physics : PCCP,
Pavel Kubát, and Kamil Lang, and Pavel Anzenbacher
January 1981, Acta pharmaceutica Suecica,
Pavel Kubát, and Kamil Lang, and Pavel Anzenbacher
May 1983, Acta pharmacologica et toxicologica,
Copied contents to your clipboard!